CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML

Article English OPEN
Anderson, E.; Mehta, P.; Heywood, J.; Rees, B.; Bone, H.; Robinson, G.; Reynolds, D.; Salisbury, V.; Mayer, L.;
(2018)
  • Publisher: Elsevier

CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML processing to release encapsulated drugs. Further assessment demonstrated cytotoxicity of CPX-351 to be superior to DA at 48 and 72 hours i... View more
Share - Bookmark